579 related articles for article (PubMed ID: 8996530)
1. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency.
Nissen C
Eur J Cancer; 1994; 30A Suppl 3():S12-4. PubMed ID: 7535065
[TBL] [Abstract][Full Text] [Related]
3. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers--a comparative study.
Höglund M; Smedmyr B; Bengtsson M; Tötterman TH; Cour-Chabernaud V; Yver A; Simonsson B
Eur J Haematol; 1997 Sep; 59(3):177-83. PubMed ID: 9310126
[TBL] [Abstract][Full Text] [Related]
5. Comparison of filgrastim and lenograstim in pediatric solid tumors.
Sarı N; Dalva K; Ilhan IE
Pediatr Hematol Oncol; 2013 Oct; 30(7):655-61. PubMed ID: 24050764
[TBL] [Abstract][Full Text] [Related]
6. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
7. Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors.
Stroncek DF; Clay ME; Smith J; Ilstrup S; Oldham F; McCullough J
Transfusion; 1996 Jul; 36(7):596-600. PubMed ID: 8701454
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) in healthy male volunteers.
Houston AC; Stevens LA; Cour V
Br J Clin Pharmacol; 1999 Mar; 47(3):279-84. PubMed ID: 10215752
[TBL] [Abstract][Full Text] [Related]
10. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?
Höglund M
Med Oncol; 1998 Dec; 15(4):229-33. PubMed ID: 9951685
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo neutrophil function in response to three different doses of glycosylated rHuG-CSF (Lenograstim).
Turzanski J; Crouch SP; Fletcher J; Hunter A
Br J Haematol; 1997 Jan; 96(1):46-54. PubMed ID: 9012686
[TBL] [Abstract][Full Text] [Related]
12. Actin polymerization in neutrophils from donors of peripheral blood stem cells: divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor.
Carulli G; Mattii L; Azzarà A; Brizzi S; Galimberti S; Zucca A; Benedetti E; Petrini M
Am J Hematol; 2006 May; 81(5):318-23. PubMed ID: 16628714
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
14. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.
Stroncek DF; Clay ME; Petzoldt ML; Smith J; Jaszcz W; Oldham FB; McCullough J
Transfusion; 1996 Jul; 36(7):601-10. PubMed ID: 8701455
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor.
Falanga A; Marchetti M; Evangelista V; Manarini S; Oldani E; Giovanelli S; Galbusera M; Cerletti C; Barbui T
Blood; 1999 Apr; 93(8):2506-14. PubMed ID: 10194429
[TBL] [Abstract][Full Text] [Related]
17. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
Kim IH; Park SK; Suh OK; Oh JM
Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim).
Ono M
Eur J Cancer; 1994; 30A Suppl 3():S7-11. PubMed ID: 7535073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]